Globus Medical, Inc. (GMED)
NYSE: GMED · Real-Time Price · USD
92.46
+2.30 (2.55%)
At close: Jan 14, 2026, 4:00 PM EST
91.71
-0.75 (-0.81%)
After-hours: Jan 14, 2026, 7:22 PM EST
Globus Medical Stock Forecast
Stock Price Forecast
The 12 analysts that cover Globus Medical stock have a consensus rating of "Buy" and an average price target of $95.92, which forecasts a 3.74% increase in the stock price over the next year. The lowest target is $64 and the highest is $115.
Price Target: $95.92 (+3.74%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Globus Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 5 | 6 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 5 | 5 | 6 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 14 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $105 → $112 | Strong Buy | Maintains | $105 → $112 | +21.13% | Jan 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $90 → $115 | Buy | Reiterates | $90 → $115 | +24.38% | Jan 8, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $90 → $105 | Strong Buy | Maintains | $90 → $105 | +13.56% | Dec 17, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $92 → $100 | Buy | Maintains | $92 → $100 | +8.15% | Dec 17, 2025 |
| Freedom Capital Markets | Freedom Capital Markets | Hold Initiates $87 | Hold | Initiates | $87 | -5.91% | Dec 17, 2025 |
Financial Forecast
Revenue This Year
2.94B
from 2.52B
Increased by 16.86%
Revenue Next Year
3.18B
from 2.94B
Increased by 8.05%
EPS This Year
3.87
from 0.75
Increased by 416.10%
EPS Next Year
4.21
from 3.87
Increased by 8.64%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 3.0B | 3.3B | ||
| Avg | 2.9B | 3.2B | ||
| Low | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 20.9% | 12.6% | ||
| Avg | 16.9% | 8.1% | ||
| Low | 10.7% | 2.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 4.01 | 4.52 | ||
| Avg | 3.87 | 4.21 | ||
| Low | 3.68 | 3.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 434.8% | 16.7% | ||
| Avg | 416.1% | 8.6% | ||
| Low | 391.3% | -2.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.